Cortagen is a synthetic peptide of four amino acids, one of a group of short synthetic peptides studied as peptide bioregulators [3][12]. A peptide bioregulator in this literature is a short synthetic peptide, from two to four amino acids in the papers reviewed, modeled on peptides found in a tissue extract and given to shift gene activity in a particular tissue [5][12]. Cortagen is modeled on a fraction of Cortexin, a polypeptide extract of brain cortex used clinically for memory, attention and brain cortical processes [9][5]. Cortexin is an extract rather than a single protein, so it has no single chain length to quote. That origin separates cortagen from peptides cut from a single known parent protein.
Cortagen's research record begins with a 2000 rat study of sciatic nerve repair by L. N. Turchaninova, V. Kh. Khavinson and colleagues at the Institute of Bioregulation and Gerontology in St. Petersburg [1]. The peptide itself was built by directed synthesis from the amino acid analysis of Cortexin [5]. One relative in the same series is Epitalon, a tetrapeptide that differs by a single amino acid and was tested beside cortagen in the immune and chromatin experiments described below [8][4].
The research interest is concentrated in three places: recovery after nerve injury, the brain under ischemic stress, and the packing of DNA in aging cells [1][10][4]. A separate line of work, gene expression in the heart, points to effects beyond nervous tissue [5]. As of October 2026, no FDA-approved drug product containing cortagen is listed in Drugs@FDA and no registered clinical trial of it is listed on ClinicalTrials.gov [16][17]. Neither the WADA 2026 Prohibited List nor the NCAA 2026-27 banned list names it [13][14].
Key takeaways
- Cortagen is a synthetic tetrapeptide modeled on a fraction of Cortexin, a polypeptide extract of brain cortex, and studied as a short peptide bioregulator [5][9].
- Animal work reports faster regeneration and faster nerve conduction after sciatic nerve injury, less oxidative damage in the brain, and behavioral changes in mice, each from a single laboratory [1][7][9].
- Human data are limited to lymphocytes studied outside the body [4][12]. No clinical trial is registered, and the 2026 WADA list does not name the peptide [13][17].
How it works
An epigenetic model: chromatin, heterochromatin and ribosomal genes
Cortagen's best-developed mechanism is epigenetic: it changes how tightly DNA is packed. Epigenetics is the study of changes in gene activity that do not alter the DNA code. Chromatin is the packaging of DNA around histone proteins, and heterochromatin is the tightly packed form that keeps genes quiet. Euchromatin is the open form, and ribosomal genes are the DNA instructions for the RNA of the ribosome, the cell's protein factory. Those genes sit in nucleolus organizer regions, the chromosome stalks that build the nucleolus.
The 2004 study took leukocytes from donors aged 75 to 88 and measured ribosomal gene activity, heterochromatin melting, structural heterochromatin on chromosomes 1, 9 and 16, and facultative heterochromatin [4]. All five peptides tested, cortagen among them, activated ribosomal genes and decondensed chromatin. Decondensation of chromosome 1 pericentromeric chromatin appeared with epitalon, livagen and prostamax, and chromosome 9 changes with epitalon and livagen; cortagen did not produce those site-specific changes [4].
The 2020 study repeated the question with lymphocytes from donors aged 75 to 88 and 20 to 40 and a panel of four short peptides that included cortagen [12]. It measured heterochromatin parameters by differential scanning calorimetry, ribosomal gene activity at nucleolus organizer regions, C-heterochromatin, and sister chromatid exchanges, which are swaps between sister chromatids that the authors used as a marker of chromatin opening. The panel decondensed total, constitutive and facultative heterochromatin, raised exchanges in telomeric heterochromatin and lowered them in the medial chromosome arms. The authors concluded that each peptide selectively opens a specific chromosome region, releasing inactive genes. Neither abstract reports a direct measurement of cortagen binding to DNA or histones.
Gene expression in the heart
Cortagen also changes gene expression outside the nervous system, which points to effects beyond nervous tissue [5]. The 2004 heart study used cDNA microarrays, a method that measures the messenger RNA levels of thousands of genes at once, on heart tissue from 6-month-old female CBA mice given five daily injections [5]. Of 15,247 transcripts, 234 clones, or 1.53 percent, changed significantly and matched 110 known genes, with a maximum increase of 5.42-fold and a maximum decrease of 2.86-fold. A comparison with vilon, epitalon and melatonin found both shared and cortagen-specific changes.
The change covers 1.53 percent of transcripts, and the authors framed the work as a search for molecular targets in tissue [5]. The abstract reports no peptide concentration in blood or tissue, so the exposure that produced the shift is described only as an injected course. The result does show that a four-amino-acid peptide can produce a measurable, multi-gene response in an organ far from the brain.
Nerve regeneration and neuronal excitability
The sciatic nerve is the large nerve that runs from the lower spine down the leg, and cutting or crushing it gives a standard model of peripheral nerve regeneration. In the 2000 study, rats had the nerve cut and sutured, then received 10 micrograms per kilogram of cortagen intramuscularly each day for 10 days [1]. The abstract reports a 27 percent increase in the growth rate of regenerating fibers and a 40 percent increase in conduction velocity. Conduction velocity is the speed at which an electrical impulse travels along a nerve fiber, so a faster velocity means the regenerating fibers carry signals more quickly.
A 2002 report is titled "The delayed effect of cortagen on the restoration of injured nerve function" [2]. PubMed lists no abstract for it, so the design, dose and size of that experiment cannot be checked here.
Direct recordings from single neurons show a membrane-level action [11]. The experiments used identified neurons from the pedal ganglia of the mollusk Planorbarius corneus, with intracellular microelectrodes and voltage-clamp recording of ionic currents. From 0.1 to 100 micromolar, cortagen hyperpolarized the cells by 2 to 3 mV, meaning it made the inside of the membrane more negative, and reduced their spontaneous activity. The authors read that shift as an activating, neuron-protective action. At 1000 micromolar the peptide depolarized cells by 2 to 4 mV, and at 10 millimolar it produced 80 to 90 percent inhibition of sodium and calcium currents, which the authors called nonspecific and toxic.
Oxidative stress and the ischemic brain
Cortagen has been tested against oxidative stress, the chemical damage that follows an excess of reactive oxygen species. Lipid peroxidation is the oxidation of fats in cell membranes, and oxidative modification of proteins is the addition of oxidized groups to protein side chains. In rats, injections of epitalon and cortagen lowered lipid peroxidation products and oxidative protein modification in serum and cerebral cortex [7]. The same measurements showed lower antioxidant activity, an unexpected pairing that the abstract reports without explaining.
The ischemia work tested the same idea in a disease model. Chronic brain ischemia is a long-running reduction in blood flow to the brain, and the 2011 study used rats with high and low resistance to low oxygen [10]. Cortagen and Cortexin both accelerated recovery of disturbed individual behavior and prevented excessive lipid peroxidation and a fall in antioxidant activity in brain tissue. The abstract treats the two drugs together and gives no separate dose or effect size.
A tissue-specific profile: immune signals
The immune data are the most variable part of the record, and they set a limit on how broad the peptide's action is. A comitogen is a signal that pushes lymphocytes to divide alongside another stimulus, and sphingomyelinase is an enzyme that releases a lipid messenger from the cell membrane. In mouse thymocytes, vilon produced the strongest comitogenic effect and the largest rise in sphingomyelinase activity, epitalon was weaker, and cortagen produced no comitogenic effect and stimulated the enzyme less than vilon [3].
A 2005 study looked at interleukin-2, a cytokine that drives T-cell growth, in the hypothalamus of rats after peptide injection [6]. In situ hybridization on brain sections showed that vilon, epitalon and cortagen changed interleukin-2 messenger RNA in some hypothalamic structures, and the effect depended on when and how the peptide was given. The abstract gives no direction or size for the change.
Chickens hypophysectomized early in the neonatal period develop anemia, cellular and humoral immune deficiency, hypercoagulation and impaired fibrinolysis by day 45, and old birds show milder versions of the same shifts [8]. Forty days of epitalon corrected those measures; forty days of cortagen did not. That result does not rule out an immune effect in another model, but it weakens the case for one.
What has been studied in humans
No controlled human trial of cortagen has been published, and no registered study is listed on ClinicalTrials.gov [17]. The human data in the literature come from lymphocytes studied outside the body, so they measure a cell response rather than a clinical effect [4][12].
Both human-cell studies worked with lymphocytes from donors, and both included donors aged 75 to 88. The 2004 study found that all five peptides tested, cortagen among them, activated ribosomal genes and decondensed chromatin; chromosome 1 decondensation appeared with epitalon, livagen and prostamax, and chromosome 9 changes with epitalon and livagen [4]. The 2020 study found that a panel including cortagen decondensed total, constitutive and facultative heterochromatin and shifted sister chromatid exchanges [12]. Neither abstract reports a dose, a dosing schedule or an adverse event.
One paper makes a larger claim about human use. A 2004 report on mouse heart gene expression states in its abstract that cortagen showed a pronounced therapeutic effect on posttraumatic recovery of peripheral nerve tissue in humans [5]. The abstract presents no patient data, dose or outcome measure, and no trial record supports the statement. No other paper in the literature reviewed reports patient data for cortagen.
Doses studied in human trials
As of October 2026, Cortagen has no FDA-approved product and no registered clinical trial. The studies below are laboratory and animal studies.
10 micrograms per kilogram intramuscularly daily for 10 days after nerve transection and suturing
Rats after sciatic nerve transection and suturing; group sizes not stated in the abstract
0.01, 0.03 or 0.10 mg/kg intraperitoneally
Male CD-1 mice, 8 per group
0.1 to 10,000 micromolar cortagen applied to isolated neurons
Pedal ganglia neurons of the mollusk Planorbarius corneus
Lab and animal studies
Preclinical means work in cells, tissue or animals before human testing. The cortagen literature covers nerve repair, brain ischemia, oxidative stress, behavior and gene expression, and several of the papers come from laboratories in St. Petersburg [1][5].
The nerve work is the most direct. In rats, a cut and sutured sciatic nerve treated with daily cortagen grew fibers faster and conducted impulses faster [1]. A 2002 follow-up is titled "The delayed effect of cortagen on the restoration of injured nerve function," but PubMed lists no abstract for it [2]. The behavioral work used mice and found a narrow stimulant effect at 0.03 mg/kg, with anxiogenic effects at other doses after repeated treatment [9]. The ischemia work found faster behavioral recovery and less oxidative damage in brain tissue when cortagen and Cortexin were tested in the same model, though the abstract does not separate the two drugs [10].
The cell work supplies the mechanistic idea. Lymphocytes from older donors showed ribosomal gene activation and chromatin decondensation after peptide exposure [4][12]. A mouse heart microarray found 110 known genes with changed expression after five daily injections, which shows a transcriptome response in heart tissue [5]. The immune experiments cut the other way: cortagen had no comitogenic effect on mouse thymocytes and failed to correct immune or clotting parameters in hypophysectomized chickens where epitalon worked [3][8].
Three limits run through the whole set. Doses, group sizes and statistics are missing from several abstracts, and the two human-cell studies test peptide panels rather than cortagen alone [4][12]. No abstract reports plasma levels, tissue distribution, half-life or a toxicology program. The neuronal recordings come from an invertebrate and used concentrations up to 10 millimolar [11].
Research in detail
Rat study of nerve transection and suture with daily peptide injection · Rats after sciatic nerve transection and suturing; group sizes not stated in the abstract
The growth rate of regenerating nerve fibers rose 27 percent and conduction velocity rose 40 percent.
Evidence scope: Abstract reviewed; full text not read. Group sizes, controls and statistics are not in the abstract, and the work comes from one research group.
Ex vivo cytogenetic study of donor lymphocytes · Leukocytes from donors aged 75 to 88 years
All five peptides, cortagen among them, activated ribosomal genes and decondensed chromatin; chromosome 1 decondensation appeared with epitalon, livagen and prostamax, and chromosome 9 changes with epitalon and livagen.
Evidence scope: Abstract reviewed; full text not read. Panel design with five peptides and no dose given; cells studied outside the body with no clinical endpoint.
In vivo rat study of tetrapeptide injections with serum and brain measurements · Rats; number and strain not stated in the abstract
Epitalon and cortagen injections lowered lipid peroxidation products and oxidative protein modification in serum and cerebral cortex, with a parallel fall in measured antioxidant activity.
Evidence scope: Abstract reviewed; full text not read. No dose, group size or statistics appear in the abstract, and the antioxidant result is unexplained.
Study in hypophysectomized and aged chickens with 40 days of peptide treatment · Chickens hypophysectomized in the neonatal period and old birds
Epitalon corrected anemia, cellular and humoral immune deficiency, hypercoagulation and inhibited fibrinolysis; cortagen did not affect the measured parameters.
Evidence scope: Abstract reviewed; full text not read. A negative result in birds, with dose and group sizes not stated.
Behavioral pharmacology study with acute and 5-day dosing, using the elevated plus maze and locomotor activity habituation · Male CD-1 mice, 8 per group
0.03 mg/kg increased locomotion after acute and repeated dosing with few effects on anxiety-related behavior; after 5 days the Cortexin reference and the other cortagen doses produced anxiogenic effects.
Evidence scope: Full text reviewed. Mouse behavior only; activity and maze scores do not establish a mechanism.
Rat model of chronic brain ischemia with behavioral and biochemical endpoints · Rats with high and low resistance to hypoxia
Cortagen and Cortexin accelerated recovery of individual behavior and prevented excessive lipid peroxidation and a fall in antioxidant activity in brain tissue.
Evidence scope: Abstract reviewed; full text not read. The two drugs are treated together, and the abstract gives no separate dose or effect size.
Intracellular recording and voltage clamp in identified mollusk neurons · Pedal ganglia neurons of the mollusk Planorbarius corneus
0.1 to 100 micromolar hyperpolarized neurons by 2 to 3 mV and reduced spontaneous activity; 1000 micromolar depolarized them by 2 to 4 mV; 10 millimolar produced 80 to 90 percent inhibition of sodium and calcium currents.
Evidence scope: Abstract reviewed; full text not read. Invertebrate neurons and concentrations up to 10 millimolar; the authors called the high-concentration effects nonspecific and toxic.
Ex vivo molecular-cytogenetic study of cultured lymphocytes · Lymphocytes from donors aged 75 to 88 and 20 to 40 years
A panel including cortagen deheterochromatinized total, constitutive and facultative heterochromatin, raised sister chromatid exchanges in telomeric heterochromatin and lowered them in the medial chromosome arms.
Evidence scope: Abstract reviewed; full text not read. Panel design with no cortagen-specific dose-response; cultured cells only.
History and where it stands today
The literature reviewed here runs from a 2000 nerve-repair paper to a 2020 chromatin study. No registered clinical trial of the peptide is listed on ClinicalTrials.gov [17].
- 2000A 2000 paper described daily intramuscular cortagen at 10 micrograms per kilogram for 10 days in rats after sciatic nerve transection and suturing, with faster fiber growth and faster conduction [1].
- 2002A 2002 Doklady Biological Sciences report is titled "The delayed effect of cortagen on the restoration of injured nerve function," and a mouse thymocyte study found no comitogenic effect and weaker sphingomyelinase stimulation than vilon [2][3].
- 2004Two 2004 papers widened the picture: lymphocytes from donors aged 75 to 88 showed ribosomal gene activation and chromatin decondensation, and a mouse heart microarray found 110 known genes with changed expression after five daily injections [4][5].
- 2007Rats injected with epitalon and cortagen showed lower lipid peroxidation products and less oxidative protein modification in serum and cerebral cortex, alongside lower measured antioxidant activity [7].
- 2008In chickens hypophysectomized in the neonatal period and in old birds, epitalon corrected anemia, immune deficiency and clotting changes, while cortagen did not affect the measured parameters [8].
- 2009In CD-1 mice, 0.03 mg/kg intraperitoneally increased locomotion after acute and repeated dosing, while the 0.01 and 0.10 mg/kg doses produced anxiogenic effects after acute and repeated treatment [9].
- 2011In rats with chronic brain ischemia and different tolerance to hypoxia, cortagen and Cortexin accelerated behavioral recovery and prevented excessive lipid peroxidation and a fall in antioxidant activity in brain tissue [10].
- 2013Intracellular recordings from mollusk neurons showed 2 to 3 mV hyperpolarization at 0.1 to 100 micromolar and 80 to 90 percent inhibition of sodium and calcium currents at 10 millimolar, which the authors called nonspecific and toxic [11].
- 2020A molecular-cytogenetic study of cultured lymphocytes from donors aged 75 to 88 and 20 to 40 found that a panel including cortagen decondensed total, constitutive and facultative heterochromatin [12].
- October 2026As of October 2026, no FDA-approved drug product containing cortagen is listed in Drugs@FDA and no registered clinical trial is listed on ClinicalTrials.gov [16][17]. Neither the 2026 WADA list nor the NCAA 2026-27 list names it [13][14], and the FDA compounding safety-risk list does not name it either [15]. WADA's S0 catch-all and the S2 related-substances language remain the routes by which it could be covered [13].
How it compares with related peptides
Epitalon is a close relative in the same tetrapeptide series and differs by one amino acid [8]. In the 2008 chicken study, epitalon corrected anemia, immune deficiency and clotting changes that cortagen did not change, and in the 2004 lymphocyte study it decondensed chromosome 1 chromatin and changed chromosome 9, effects cortagen did not produce [8][4]. Both peptides appear in the same aging and chromatin experiments, with effects that depend on the exact molecule.
Vilon is a dipeptide, two amino acids long, and the most potent of the group in the thymocyte assay: it drove comitogenic proliferation and raised sphingomyelinase activity, while cortagen produced no comitogenic effect and a weaker enzyme response [3]. Vilon is studied as an immune signal, and cortagen's literature centers on nerve repair and chromatin [3][1]. The size difference is part of the comparison, two amino acids against four, but the assay result shows that length alone does not predict activity.
Livagen is another short peptide in the same chromatin panel [4]. In lymphocytes from donors aged 75 to 88, livagen decondensed chromosome 1 pericentromeric chromatin and also changed chromosome 9, effects cortagen did not produce [4]. Both are studied for age-related chromatin changes, and the comparison shows that sharing a length does not mean sharing a chromosome target.
Side effects and safety signals
The safety record is thin and almost entirely preclinical, with the clearest signals coming from behavior in mice and from high concentrations applied to neurons.
- No controlled human safety data exist: the human material in the literature is lymphocytes studied outside the body, not dosed volunteers [4][12].
- In CD-1 mice, 0.03 mg/kg increased locomotion, and a 5-day regimen at other doses produced anxiogenic effects [9].
- In mollusk neurons, 1000 micromolar depolarized cells and 10 millimolar inhibited sodium and calcium currents by 80 to 90 percent, effects the authors called nonspecific and toxic [11].
- No pharmacokinetic data appear in the abstracts reviewed: none reports absorption, distribution, half-life or metabolite levels [1][7].
- The animal studies reviewed report behavioral, biochemical or electrophysiological endpoints; none is a repeat-dose toxicology, genotoxicity, developmental or carcinogenicity study [1][7][8].
- Cortagen did not correct immune or clotting parameters in hypophysectomized or old chickens, so an immune benefit is not established [8].
- A 2004 paper refers to human therapeutic use after peripheral nerve injury without reporting patients, dose or outcomes, so that statement cannot support a safety assessment [5].
The future: what's next for Cortagen
No interventional study of cortagen is registered [17]. A ClinicalTrials.gov intervention search on October 23, 2026 returned no record for the peptide, and the sources reviewed contain no protocol, enrollment target or primary endpoint. An initial human study would need a pharmacokinetic phase to measure plasma levels and half-life, since none of the abstracts reports either [1][7]. It would also need a dose range justified by the animal work, which used 10 micrograms per kilogram in rats and 0.01 to 0.10 mg/kg in mice [1][9].
No regulatory decision is pending for cortagen in the sources reviewed. No FDA-approved drug product containing cortagen is listed in Drugs@FDA [16], and FDA's compounding safety-risk list does not name it [15]. The 2026 WADA list and the NCAA 2026-27 list do not name it, so the catch-all classes are the main route by which it could be covered [13][14].
The research that would matter most is replication. The nerve-repair result rests on one 2000 report with no group sizes in the abstract, and the 2002 follow-up has no available abstract [1][2]. The chromatin work comes from a small circle of collaborators in Tbilisi and St. Petersburg, and the 2004 and 2020 papers test panels rather than cortagen alone [4][12]. Independent laboratories, stated doses and a direct binding assay for chromatin would turn the epigenetic model from a plausible story into a mechanism. Public identity and purity documents would support that work, and the COA library collects them; how to verify a COA explains what the documents should show.
- Whether cortagen binds DNA, histones or another chromatin protein directly, since the published cell studies measure the result rather than the binding step [4][12].
- Which animal results survive replication with stated doses, group sizes and independent laboratories [1][2].
- What concentration of the peptide reaches nerve or brain tissue after the doses used in rats and mice [1][9].
- Whether the single amino acid that separates cortagen from epitalon explains the difference in their chromatin and immune effects [8][4].